中国P站

Osteonecrosis; Avascular necrosis; Oncology; Transplant; Corticosteroids; Immunosuppression; Bone health; Cancer survivorship; Orthopedic complications; Bone necrosis

Introduction

Osteonecrosis is an orthopedic complication of growing concern, especially among oncology and transplant patients. Characterized by the death of bone tissue due to reduced blood supply, it commonly affects weight-bearing joints such as the hip, knee, and shoulder. The condition often progresses silently until significant joint damage occurs, leading to chronic pain, disability, and the need for surgical intervention [1]. In recent years, the increasing use of therapies associated with osteonecrosis risk such as high-dose corticosteroids, cytotoxic drugs, and immune-modulating treatments has correlated with a rise in its incidence in these populations. With improved survival in cancer and post-transplant care, addressing the long-term skeletal consequences like osteonecrosis is crucial for comprehensive patient management [2].

Description

Osteonecrosis is pathologically defined by the death of bone components, particularly osteocytes and bone marrow, following a critical reduction or cessation in blood flow. In oncology patients, factors contributing to osteonecrosis include high-dose corticosteroid use for chemotherapy-induced nausea or treatment of hematologic malignancies, radiation-induced vascular injury, and the direct impact of chemotherapeutic agents on endothelial cells [3]. Hematological malignancies such as leukemia, lymphoma, and multiple myeloma carry a particularly high risk due to treatment regimens that heavily rely on steroids and aggressive chemotherapies.

In transplant patients, osteonecrosis primarily arises from chronic corticosteroid use required to prevent graft rejection. Kidney, liver, heart, and hematopoietic stem cell transplant recipients are especially vulnerable. The cumulative steroid dose, duration of treatment, and individual susceptibility all play a role in pathogenesis. Additionally, factors like impaired lipid metabolism, coagulation abnormalities, and endothelial dysfunction may further predispose these individuals [4]. Clinically, osteonecrosis may remain asymptomatic in early stages or present with vague joint pain. As the disease progresses, pain becomes persistent, functional limitations increase, and imaging may reveal joint space narrowing, sclerosis, and subchondral fractures. Magnetic resonance imaging (MRI) remains the most sensitive tool for early detection, often identifying changes before radiographic signs become evident. Bone scans and CT scans can also support diagnosis in complex cases [5].

Discussion

Understanding the multifactorial nature of osteonecrosis in oncology and transplant patients is key to both prevention and management. Corticosteroids, the most implicated agents, affect bone through various mechanisms: they reduce osteoblast function, increase apoptosis of osteocytes, and cause fat embolism, all of which contribute to impaired microcirculation. Additionally, chemotherapy-induced endothelial damage and radiation-induced fibrosis can further compromise vascular integrity in bone tissue [6].

Certain cancer treatments exacerbate osteonecrosis risk. For instance, antiangiogenic agents like bevacizumab may hinder bone repair by disrupting vascular regeneration. Bisphosphonates and denosumab, while protective against skeletal-related events, have been associated with osteonecrosis of the jaw (ONJ), a distinct but related condition. In transplant populations, calcineurin inhibitors such as cyclosporine and tacrolimus may synergize with steroids to increase the risk [7]. Preventive strategies are essential and should be tailored to high-risk groups. Minimizing cumulative steroid exposure, employing steroid-sparing immunosuppressive regimens, and using alternative antiemetic or immunomodulatory therapies can reduce the incidence. Early screening with MRI, especially in symptomatic or high-risk asymptomatic patients, allows for timely intervention [8].

Management of osteonecrosis is stage-dependent. In early-stage disease, conservative measures including activity modification, analgesia, bisphosphonates, and physical therapy may offer symptom relief and delay progression. Core decompression, which aims to reduce intraosseous pressure and stimulate revascularization, has shown efficacy in certain cases. Advanced disease often necessitates surgical options such as osteotomy or total joint arthroplasty, particularly when structural collapse impairs joint function [9]. Rehabilitation and long-term follow-up are integral to recovery and quality of life. Orthopedic consultation should be sought early in suspected cases. Moreover, patient education on symptom vigilance, adherence to immunosuppressive protocols, and lifestyle modifications like smoking cessation and lipid control further enhance outcomes. Research continues to explore genetic predispositions to osteonecrosis, with polymorphisms in genes involved in lipid metabolism, coagulation, and corticosteroid metabolism being investigated. The role of stem cell therapy and tissue engineering in regenerating necrotic bone is an emerging field with promising implications [10].

Conclusion

Osteonecrosis represents a significant and often underrecognized complication in oncology and transplant patients. As survival improves and treatment regimens become more intensive, awareness of this condition’s prevalence and impact must increase. Through a multidisciplinary approach encompassing early diagnosis, preventive care, and individualized treatment strategies, clinicians can mitigate the burden of osteonecrosis and enhance patient quality of life. Continued research into its molecular underpinnings and therapeutic innovations will further support effective management in these vulnerable populations.

References

1. Payne JD, Stickgold R, Swanberg K, Kensinger EA (2008) . Psychol Sci 19: 781-788.

   , ,

2. Li W. Ma L, Yang G, Gan WB (2017) . Nat Neurosci 20: 427-437.

   , ,

3. Le Bom O (2020) . Sleep Medicine 70: 6-16.

   , ,

4. Roberts RE, Duong HT (2014) Sleep 37: 239-244.

   , ,

5. Sejbuk M, Mironczuk-Chodakowska I, Witkowska AM (2022) . Nutrients 14: 1912.

   , ,

6. de Mendonça FMR, de Mendonça GPRR, Souza LC, Galvão LP, Paiva HS, et al. (2023) . CNS Neurol Disord Drug Targets 22: 172-179.

   , ,

7. de Aquino Junior AE, Rodrigues TZ, Garcia V, Simão G, Carbinatto FM, et al. (2022) Conjugated and Synergistic Therapies in the treatment of Covid 19 Dysfunction - Pain, Weakness, Parestheria, Respiratory Condition, Memory, Olfactory and Taste: Case Series. J Nov Physiother 12: 545.

8. de Aquino Junior AE, Carbinatto FM, Franco DM, Silva JD, Bruno A, et al. (2021) The Laser and Ultrasound: The Ultra Laser like Efficient Treatment to Fibromyalgia by Palms of Hands: Comparative Study. J Nov Physiotherapies 11: 447.

9. de Aquino Junior AE, Carbinatto FM, Rodrigues TZ, Garcia V, et al. (2023) The Regulatory Action of Fibro fog: Pain, Quality of Life, Sleep, Anxiety and Depression observed after 42 Months of Treatment: A Case Report. J Nov Physiother 13: 2.

10. de Aquino Junior AE, Carbinatto FM, Tomaz CDSR, Bagnato VS (2022) Photosonic treatment and Fibromyalgia: The Effect on Brain Compliance-Case Report. J Nov Physiother 12: 510.